Loading
Life sciences · Journal article
Frontiers in Immunology · September 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Leptomeningeal metastasis (LM) is a devastating form of central nervous system (CNS) dissemination in lung cancer, particularly non-small cell lung cancer (NSCLC). Current treatment frameworks emphasize CNS drug penetration, oncogenic driver evolution, and intrathecal therapy. Emerging evidence supports viewing the cerebrospinal fluid (CSF) compartment as an active tumor-immune space, but the field remains early, with limited lung cancer-specific mechanistic and single-cell datasets. Lung cancer cells in CSF appear to adapt to low protein content, limited nutrients, fluid shear, weak matrix support, and compartmental immune surveillance. Meanwhile, available CSF studies suggest immune states marked by exhausted T cells, regulatory lymphoid programs, suppressive myeloid remodeling, cytokine dysregulation, and tumor-supportive signaling. This review summarizes the CSF metastatic niche, tumor adaptation, immune-cell states, tumor-immune crosstalk, therapy-associated remodeling, and CSF multi-omics in lung cancer LM. We propose that CSF-guided profiling may help generate immune-state classifications and inform future targeted, intrathecal, immune, or combination strategies, while requiring prospective validation before routine treatment guidance.